Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and hyperinflammation shows evidence of treatment response in all 13 non-ventilated patients dosed –– Preparing registrational development program of mavrilimumab in patients with COVID-19 pneumonia and hyperinflammation –– Phase 2 trial of vixarelimab in prurigo nodularis met primary efficacy endpoint: statistically significant reduction of weekly average WI-NRS at Week 8 – HAMILTON, Bermuda, April 28, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today reported first quarter 2020 financial results and highlighted recent corporate and pipeline activity. “Kiniksa continued to advance its clini
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.MarketBeat
- Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KNSA&utm_campaign=getratings&utm_medium=online&utm_source=MaMarketBeat
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KNSA&utm_campaign=getratings&utm_medium=online&utm_source=MaMarketBeat
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $45.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
KNSA
Earnings
- 10/28/25 - Miss
KNSA
Sec Filings
- 12/1/25 - Form 4
- 11/26/25 - Form 144
- 11/19/25 - Form 4
- KNSA's page on the SEC website